When we administered tenfold (1 × 107) human L1CAM-specific CAR T cell doses on three consecutive days and started treatment earlier when tumors became just palpable (mean diameter 30–100 mm3), L1CAM-SS-28/ζ CAR T cells were able to eradicate the tumor in only 1 of 4 mice without recurrence during the observation period of >100 days (Figure 3D). This evidence concerns the gene L1CAM and neoplasm.